NanoString Technologies has launched its nCounter Human Organ Transplant panel, a new gene expression panel for evaluating the immune response following organ transplantation. The firm said that it created the assay in collaboration with the Banff Foundation for Allograft Pathology. The panel covers 770 genes and is customizable. It is designed for use with the predominant transplant organs including kidney, heart, lung, and liver. Genes included on the panel are involved in 37 pathways that are components of the immune response, tissue injury, and mechanisms of action for immunosuppressive drugs. The panel also includes probes to detect common viral infections that can cause issues with transplants, including BK polyomavirus, cytomegalovirus, and Epstein-Barr virus.